Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 15/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21136887 | 1.00 | NT5E (0.71) | NT5EADORA3ADORA1CA5A | |
| SCHEMBL21136889 | 0.93 | NT5E (0.67) | NT5EADORA3ADORA1 | |
| SCHEMBL21136489 | 0.93 | NT5E (0.67) | NT5EADORA3ADORA1 | |
| SCHEMBL21136515 | 0.92 | NT5E (0.66) | NT5EADORA3ADORA1 | |
| SCHEMBL21136528 | 0.92 | NT5E (0.66) | NT5EADORA3ADORA1 | |
| SCHEMBL17010790 | 0.92 | ADORA1 (0.72) | NT5EADORA3ADORA1CA5A | |
| SCHEMBL15305336 | 0.92 | ADORA1 (0.72) | NT5EADORA3ADORA1CA5A | |
| SCHEMBL24784523 | 0.90 | ADORA1 (0.61) | NT5EADORA3ADORA1CA5A | |
| SCHEMBL21136568 | 0.89 | ADORA3 (0.62) | NT5EADORA3ADORA1 | |
| SCHEMBL21136169 | 0.89 | NT5E (0.72) | NT5EADORA3ADORA1CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Atea Pharmaceuticals, Inc. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | NSUN2, ADAR, NSUN3 | NT5E 90/4885ADORA3 67/4885ADORA1 121/4885 |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | NT5E 92/4885ADORA3 59/4885ADORA1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.